47th Annual Southeastern Wisconsin Cancer Conference: Selected Updates in Genitourinary
Milwaukee, WI US
March 21, 2015

The options for diagnosing, treating and managing cancer are constantly evolving. The primary care provider is an essential partner in the diagnosis and management of cancer. This conference is designed to present new developments in the diagnosis and treatment of genitourinary cancers by experts in their respective fields. Physicians, nurses and other allied healthcare professionals will be presented with a review of recent data of the epidemiology, screening, diagnosis, staging and multimodality, evidence- based management of genitourinary cancer.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Wheaton Franciscan Healthcare. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 3.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 3.25 hours of participation for continuing education for allied health professionals.
In accordance with the Americans with Disabilities Act, the Southeastern Wisconsin Cancer Conference seeks to make this conference accessible to all. If you have a disability, which might require special accommodations, please email your needs to: info@wicancerconference.org or call (262) 523-5547.
Target Audience
- Physicians
- Physician Assistants
- Nurses
- Nurse Practitioners
- Pharmacists
- Pharmacy Technicians
- Allied Health Professionals
Learning Objectives
At the conclusion of this activity, I will be able to:
- Determine current recommendations for prostate cancer screening in general public and high risk populations.
- Identify safe and effective strategies that complement standard oncology care to manage treatment or disease related adverse events
- Determine best practice in the treatment of bladder, prostate, kidney and testicular cancer
Italian Community Center
631 E. Chicago Street
Milwaukee, WI
53202
United States
Italian Community Center
631 E. Chicago Street
Milwaukee, WI 53202-5916
414-223-2180
SEWCC Program Planning Committee
Paul Ritch, MD - Chairman
Teri Vega-Stromberg, MSN - Vice Chairman
Gerald Kallas, MD - Treasurer
Mary Kissinger, RHIA, CTR - Secretary
Deanna M. Birling, MSN, ANP-B AONP
Charles Bomzer, MD
Joseph Bovi, MD
Beth Brunner, ACS
Lynn Czaplewski, MS, RN
B.J. Gruling, RPh
Gerald Hanson, MD
Julie Jensen, RN, MSN, C-ANP
Thomas Jensen, MD
Kirk Ludwig, MD
Lisa Robinson, RHIA, CTR
Laura Raftery, MD
Carrie Ricconbono, MSN, RN, ACNS-BC, OCN
Presenters
Paul Ritch, MD
Derek Raghavan, MD
Nicholas Vogelzang, MD
Walter Stadler, MD
Lawrence Einhorn, MD
Mark Moyad, MD
All persons in control of content have NO relevant financial relationships to disclosure except the following:
Name | Company | Role With Company
|
Mark Moyad, MD | AbbVie, Max Int’l, Farr Labs | Speaker, Consulting |
Nicholas Vogelzang, MD | Janssen Biotech, Caris Life Sciences, US Oncology, DAVAOncology, Mannkind, UpToDate, Abbvie, Bavarian Nordic, Endocyte, GlaxoSmith Kline, Genentech, Celgene, Dendreon, Novartis, Pfizer, Bayer/Onyx, Exelixis | Employment, Consulting, Speaker, |
Walter Stadler, MD | Bayer, Caremark/CVS, Genentech, Johnson&Johnson, MedPacto, Merck, Millenium, Sotio | Consultant/Advisory Board |
Derek Raghavan, MD | Sanofi | Advisory Board |
Lawrence Einhorn, MD | Amgen, Biogenidec | Stock |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Available Credit
- 3.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 3.25 Hours of ParticipationHours of Participation credit.